Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Verisign Announces the Retirement of George E. Kilguss III, Executive Vice President and Chief Financial Officer
Verisign Announces the Retirement of George E. Kilguss III, Executive Vice President and Chief Financial Officer


VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that after 13 years with the Company, George E. Kilguss III

Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program
Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program


Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare

Connection Named One of Forbes America’s Best Employers
Connection Named One of Forbes America’s Best Employers


Connection (PC Connection, Inc.; NASDAQ: CNXN), a leading information technology solutions provider to business, government, healthcare, and education markets, is pleased to announce that it has

ISG Certified as ‘Great Place To Work’
ISG Certified as ‘Great Place To Work’


Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, today announced ISG India has been recognized for the sixth consecutive year as a “Great

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer


Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer


Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI

Redfin Reports Housing Supply Hits Highest Level Since 2020, But Demand Falls to Lowest Level Since 2020
Redfin Reports Housing Supply Hits Highest Level Since 2020, But Demand Falls to Lowest Level Since 2020


(NASDAQ: RDFN) — Homebuyers have the most options since 2020, but few are biting because rising housing costs have made monthly payments tough to swallow. That is according to a new report from

Investors Title Company Announces Fourth Quarter and Fiscal Year 2024 Results
Investors Title Company Announces Fourth Quarter and Fiscal Year 2024 Results


Investors Title Company (Nasdaq: ITIC) today announced results for the fourth quarter ended December 31, 2024. The Company reported net income of $8.4 million, or $4.41 per diluted share, compared

Redfin Reports Housing Supply Is Piling Up As Home Sellers Enter the Market But Buyers Stay on Sidelines
Redfin Reports Housing Supply Is Piling Up As Home Sellers Enter the Market But Buyers Stay on Sidelines


(NASDAQ: RDFN) — There are five months of for-sale supply on the market nationwide, up from 4.4 months a year earlier and the most since early 2019. That’s according to a new report from Redfin (re

Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025
Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025


Walmart Inc. (NYSE: WMT) announced it will hold a live conference call with the investment community at 7 a.m. CST on Thursday, Feb. 20, 2025, to discuss the company's fourth quarter and full-year

Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025
Walmart To Host Fourth Quarter Earnings Conference Call February 20th, 2025


Walmart Inc. (NYSE: WMT) announced it will hold a live conference call with the investment community at 7 a.m. CST on Thursday, Feb. 20, 2025, to discuss the company's fourth quarter and full-year

Howmet Aerospace Reports Fourth Quarter and Full Year 2024 Results
Howmet Aerospace Reports Fourth Quarter and Full Year 2024 Results


Howmet Aerospace (NYSE:HWM):



Fourth Quarter 2024 GAAP Financial Results




  • Revenue of $1.9 billion, up 9% year over year, driven by Commercial Aerospace, up 13%


  • Net Income of $314 million

Lincoln Electric Reports Fourth Quarter and Full Year 2024 Results
Lincoln Electric Reports Fourth Quarter and Full Year 2024 Results


Lincoln Electric Holdings, Inc. (the “Company”) (Nasdaq: LECO) today reported fourth quarter 2024 net income of $140.2 million, or diluted earnings per share (EPS) of $2.47, which included special

AI-Driven Cloud Expansion, Cost Reduction Clash in France
AI-Driven Cloud Expansion, Cost Reduction Clash in France


Enterprises in France are facing competing pressures, prompting them to reassess their public cloud investments to balance the need for AI-driven innovation and cost optimization, according to a

Copart, Inc. to Release Second Quarter Fiscal 2025 Results
Copart, Inc. to Release Second Quarter Fiscal 2025 Results


Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

Copart, Inc. to Release Second Quarter Fiscal 2025 Results
Copart, Inc. to Release Second Quarter Fiscal 2025 Results


Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

Copart, Inc. to Release Second Quarter Fiscal 2025 Results
Copart, Inc. to Release Second Quarter Fiscal 2025 Results


Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Royal Gold Concludes an Outstanding Year of Financial Performance with Records for Revenue, Operating Cash Flow and Earnings for both the Fourth Quarter and the Full Year of 2024
Royal Gold Concludes an Outstanding Year of Financial Performance with Records for Revenue, Operating Cash Flow and Earnings for both the Fourth Quarter and the Full Year of 2024


Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold,” the “Company,” “we,” “us,” or “our”) reports net income of $332.0 million, or $5.04 per share, for the year ended

Martin Midstream Partners Reports Fourth Quarter and Full Year 2024 Financial Results and Releases 2025 Guidance
Martin Midstream Partners Reports Fourth Quarter and Full Year 2024 Financial Results and Releases 2025 Guidance


Martin Midstream Partners L.P. (Nasdaq: MMLP) (“MMLP” or the “Partnership”) today announced its financial results for the fourth quarter and full year ended December 31, 2024.



Bob Bondurant

Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend
Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend


Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the full year and fourth quarter ended December 31, 2024.



CEO Remarks



“Ventas delivered strong financial

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in

Philip Morris International to Present at 2025 CAGNY Conference
Philip Morris International to Present at 2025 CAGNY Conference


Regulatory News:



Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast of a presentation by Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial

ISG Case Study Research Recognizes 50 Providers for Best-in-Class Work with Enterprise Clients
ISG Case Study Research Recognizes 50 Providers for Best-in-Class Work with Enterprise Clients


Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, said today it has recognized 50 technology and business services providers for their